CHARLESTON, S.C., Jan. 7, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ('Revolutions Medical" or the "Company") (OTCBB:RMCP), in response to a substantial increase in demand for its 1ml safety syringe from the global marketplace, has secured a 5-year contract to produce 5 million syringes per month of its RevVac 1ml fixed needle safety syringe. The production capacity can be increased to 20 million syringes per month, and shipments will begin by July 2011.
This agreement extends the Company's relationship with Medical Investment Group, LLC (MIG). MIG is currently contracted to produce the RevVac 3ml fixed needle safety syringe for delivery in April 2011. MIG will fulfill these obligations through its relationship with a certified global medical device manufacturer in China. This manufacturer currently ships medical products throughout the world and is compliant with all major international standards including FDA, CE Mark and Health Canada, as well as those required in Japan, China and India. The factory is fully ISO compliant for medical device manufacturing and has comprehensive clean rooms, packaging and sterilization facilities.
"The selection of this manufacturer in China, with its expert capabilities, provides Revolutions Medical with the ability to deliver the highest quality and cost effective product to the marketplace. With the strong performance history of this factory, we can be assured of meeting the high demand for the Company's proprietary auto retractable vacuum safety syringes," states Rich Theriault, President of Strategic Product Development (SPD) and consultant to Revolutions Medical.
"Rich Theriault has extensive years of experience working with global manufacturing and will be managing this effort. His knowledge and expertise for delivering many quality products into the medical device marketplace is vast. It is important for Revolutions Medical to continue its extensive research and development projects as it transitions into sales during second quarter of 2011," says Ron Wheet, CEO, Revolutions Medical Corporation.
The company is still on schedule to manufacture and produce all of its other RevVac syringe sizes and its RevLok interchangeable needle designs later this year. Revolutions Medical is also working on its new prefilled vacuum safety syringe technology and should have designs completed this quarter.
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved), safety blood drawing device, and the RevColorTM, RevDisplayTM and Rev3DTM software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The Company also has an exclusive license to a Breast Biopsy System (BBS) preliminary called RevTrack (FDA approved).
For additional information, please visit Revolutions Medical corporate website:
To be added to the Revolutions Medical investor email list, please email with RMCP in the subject line.
Become a RevMed fan and follow the Company on Facebook -- visit http://www.Facebook.com/Revmed
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
CONTACT: Revolutions Medical Corporation Investor Relations: Scott Key (843) 518-0437 Skey@revolutionsmedical.com